Today’s Stock Alert: Is Buying Stock Like Kite Pharma Inc After Such Increase Winning Strategy?

Today's Stock Alert: Is Buying Stock Like Kite Pharma Inc After Such Increase Winning Strategy?

The stock of Kite Pharma Inc (NASDAQ:KITE) is a huge mover today! About 748,049 shares traded hands. Kite Pharma Inc (NASDAQ:KITE) has risen 5.40% since April 27, 2016 and is uptrending. It has outperformed by 0.17% the S&P500.
The move comes after 6 months positive chart setup for the $2.43 billion company. It was reported on Nov, 30 by Barchart.com. We have $53.52 PT which if reached, will make NASDAQ:KITE worth $121.50 million more.

Analysts await Kite Pharma Inc (NASDAQ:KITE) to report earnings on March, 6. They expect $-1.82 earnings per share, down 114.12% or $0.97 from last year’s $-0.85 per share. After $-1.49 actual earnings per share reported by Kite Pharma Inc for the previous quarter, Wall Street now forecasts 22.15% negative EPS growth.

Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage

Out of 10 analysts covering Kite Pharma (NASDAQ:KITE), 9 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 90% are positive. Kite Pharma has been the topic of 23 analyst reports since August 4, 2015 according to StockzIntelligence Inc. FBR Capital maintained Kite Pharma Inc (NASDAQ:KITE) on Friday, November 13 with “Mkt Perform” rating. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Buy” rating given on Sunday, August 16 by Stifel Nicolaus. The firm earned “Mkt Perform” rating on Thursday, September 3 by FBR Capital. The company was initiated on Thursday, February 25 by Citigroup. The company was maintained on Tuesday, August 9 by Barclays Capital. The firm has “Buy” rating given on Friday, August 14 by Canaccord Genuity. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, November 13. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Equal-Weight” rating given on Wednesday, July 6 by Barclays Capital. On Monday, November 21 the stock rating was initiated by H.C. Wainwright with “Buy”. On Thursday, June 2 the stock rating was initiated by Raymond James with “Outperform”.

According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”

Insitutional Activity: The institutional sentiment increased to 1.63 in Q2 2016. Its up 0.06, from 1.57 in 2016Q1. The ratio increased, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.
First Republic Investment Mngmt holds 0.18% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 368,335 shares. Goldman Sachs Group Incorporated last reported 0% of its portfolio in the stock. Rs Management Company Limited Liability Company owns 453,501 shares or 0.23% of their US portfolio. Frontier Management Company Ltd Company last reported 0.09% of its portfolio in the stock. Teacher Retirement System Of Texas, a Texas-based fund reported 5,364 shares. Guggenheim Ltd last reported 0.01% of its portfolio in the stock. Marshall Wace Limited Liability Partnership holds 0.04% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 93,050 shares. Franklin last reported 0.01% of its portfolio in the stock. State Street last reported 0.01% of its portfolio in the stock. Cg Asset Mgmt Limited Com has invested 0.14% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Sg Americas Securities Limited Liability Company last reported 0.03% of its portfolio in the stock. Dsam (London) last reported 231,385 shares in the company. Benjamin F Edwards & Incorporated has 200 shares for 0% of their US portfolio. Comml Bank Of America Corp De holds 0% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 10,233 shares. Tekla Capital Management Ltd Co accumulated 41,000 shares or 0.08% of the stock.

Insider Transactions: Since May 31, 2016, the stock had 0 insider purchases, and 11 insider sales for $3.86 million net activity. $541,300 worth of Kite Pharma Inc (NASDAQ:KITE) shares were sold by BUTITTA CYNTHIA M. Wiezorek Jeffrey also sold $151,949 worth of Kite Pharma Inc (NASDAQ:KITE) shares. The insider DOUMANI ROY sold 14,000 shares worth $812,581.

More notable recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Fool.com which released: “Do Juno’s Struggles Make Kite Pharma a Buy?” on November 29, 2016, also Marketwatch.com with their article: “Analysts say Juno’s stock tumbles shouldn’t spill over to Bluebird, Kite …” published on November 23, 2016, Nasdaq.com published: “First Week of July 2017 Options Trading For Kite Pharma (KITE)” on November 22, 2016. More interesting news about Kite Pharma Inc (NASDAQ:KITE) were released by: Finance.Yahoo.com and their article: “Kite Pharma reports 3Q loss” published on November 09, 2016 as well as Seekingalpha.com‘s news article titled: “Kite Pharma: So Much Promise, So Many Questions” with publication date: November 07, 2016.

KITE Company Profile

Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Firm offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Firm is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment